Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Broader off-label coverage under Part D

Executive Summary

Sens. Dianne Feinstein, D-Calif., and Sam Brownback, R-Kan., urge broader access to off-label indications under Medicare Part D in a May 22 letter to the Senate Finance Committee. The senators, who co-chair the Senate Cancer Coalition, urge that Medicare legislation being drafted by the committee include a provision allowing Part D plans to consider the "full range" of evidence in making off-label coverage decisions and bring reimbursement standards for Part D "into line with coverage standards used under Medicare Part B and by commercial insurers." CMS is currently reviewing appropriate compendia for off-label coverage under Part B (1"The Pink Sheet," April 14, 2008, p. 15)

You may also be interested in...

CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July

CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals

State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts